Oral KRAS G12D inhibitor GFH375 produces ORR 40.7% and DCR 96.7% in previously treated KRAS G12D pancreatic ductal adenocarcinoma: Key readouts from ESMO 2025
A global phase I/II study of oral GFH375 in previously treated KRAS G12D mutant PDAC showed a 40.7% ORR, 96.7% DCR, median PFS 5.52 months, and manageable toxicity, supporting ongoing phase III evaluation.